# STELLAR-002 (NCT05176483)

> Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05176483
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Exelixis
- Conditions: Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC); Solid Tumor; Hepatocellular Carcinoma (HCC); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Head and Neck Squamous Cell Carcinoma (HNSCC); Clear Cell Renal Cell Carcinoma (ccRCC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Drug-Drug Interaction (DDI)
- Interventions: Zanzalintinib; Nivolumab; Ipilimumab; Nivolumab + Relatlimab; Prednisone; Docetaxel; DDI Probe Cocktail
- Enrollment: 1394
- Primary outcome: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)
- Primary outcome: Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)
- Primary outcome: Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)
- Primary outcome: Expansion Stage Cohort 10 (CRC): Overall Survival (OS)
- Primary outcome: Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)
- Primary outcome: Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without Zanzalintinib
- Primary outcome: Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without Zanzalintinib

## Commentary we found

- X threads: 25
- Podcasts: 10
- YouTube: 9
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=stellar-002-nct05176483

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05176483", "email": "<work email>"}; the inbox owner confirms by the emailed link.